Loading
Stipple Bio looks for tiny regions on cancer-cell proteins that healthy cells do not show, then builds antibodies that bind only those regions. Its first medicine is an antibody-drug conjugate expected to start human trials in early 2027.
Stipple Bio, founded in 2022 by Aaron Ring of Fred Hutchinson Cancer Center and Aashish Manglik of UCSF, uses its Pointillist platform to find tumour-specific cell surface epitopes and design binders that recognise them, with the aim of avoiding on-target, off-tumour toxicity. Its lead candidate STP-100 is an antibody-drug conjugate incorporating tumour-specific binders, expected to enter clinical studies in early 2027; its target is undisclosed. The company emerged from stealth on 6 April 2026 with an oversubscribed USD 100 million Series A co-led by RA Capital, a16z Bio+Health and Nextech Invest, with existing investors including Emerson Collective, GV, LoLa Capital Partners and GordonMD Global Investments. In June 2026 it took a multi-target licence from Lonza for ADC technology. Jeff Landau is chief executive.
| Round | Year | Amount | Source |
|---|---|---|---|
| Series A · Co-led by RA Capital, a16z Bio+Health and Nextech Invest | 2026 | $100M | stipple.bio |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Shares Andreessen Horowitz Bio + Health, RA Capital Management.
Shares RA Capital Management, Antibody-drug conjugate (ADC).
Shares RA Capital Management, Monoclonal antibodies, Antibody-drug conjugate (ADC).
Shares RA Capital Management, Antibody-drug conjugate (ADC).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/